Literature DB >> 7437255

Oxyfederine and propranolol--a controlled trial in angina pectoris.

J Whittington, E B Raftery.   

Abstract

1 A double-blind-crossover randomised trial was performed to compare the effects of oxyfedrine (maximum dose 32 mg three times daily), propranolol (maximum dose 120 mg three times daily) and placebo in 30 patients with chronic stable angina pectoris. Assessment was by means of symptom level, ECG responses to graded exercise and haematological and biochemical investigation. 2 Oxyfedrine and propranolol resulted in similar significant improvements in symptom level (P < 0.05 in both cases), and ST index (propranolol P < 0.02; oxyfedrine P < 0.05). Neither drug produced any significant changes in haematologaical or biochemical investigations and only infrequent minor side effects were noted. 3 These results indicate that oxyfedrine is a safe and well-tolerated drug with an efficacy comparable with that of propranolol in the treatment of patients with angina pectoris.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7437255      PMCID: PMC1430143          DOI: 10.1111/j.1365-2125.1980.tb01785.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

1.  Haemodynamic consequences of coronary heart disease with observations during anginal pain and on the effect of nitroglycerine.

Authors:  O MULLER; K RORVIK
Journal:  Br Heart J       Date:  1958-07

2.  Verapamil in ischaemic heart disease--quantitative assessment by serial multistage treadmill exercise.

Authors:  V Balasubramanian; P K Khanna; G R Naryanan; R S Hoon
Journal:  Postgrad Med J       Date:  1976-03       Impact factor: 2.401

3.  [The management of angina pectoris using Ildamen, a new coronary- and cardiac-active substance, in a double-blind study].

Authors:  S Greif; V Liertzer
Journal:  Arztl Forsch       Date:  1967-09-10

4.  [Stimulation of adrenergic beta-receptors in the heart of normal and reserpinized guinea pigs by oxyfedrine].

Authors:  W R Kukovetz; G Pöch
Journal:  Arzneimittelforschung       Date:  1969-09

Review 5.  Beta-adrenergic receptor blocking drugs. Mechanisms of action and clinical applications.

Authors:  S E Epstein; E Braunwald
Journal:  N Engl J Med       Date:  1966-11-17       Impact factor: 91.245

6.  Effects of ouabain on the left ventricular response to exercise in patients with angina pectoris.

Authors:  D L Glancy; L M Higgs; K P O'Brien; S E Epstein
Journal:  Circulation       Date:  1971-01       Impact factor: 29.690

Review 7.  Beta-adrenergic receptor blocking drugs in angina pectoris.

Authors:  B N Prichard
Journal:  Drugs       Date:  1974       Impact factor: 9.546

8.  [The effect of ildamen, a cardio-energetic coronary therapeutic agent, on cardiovascular dynamics].

Authors:  N Sternitzke; J A Köhler; E Lang
Journal:  Med Welt       Date:  1966-09-03

9.  Upsloping S-T segments in exercise stress testing. Six year follow-up study of 438 patients and correlation with 248 angiograms.

Authors:  R J Stuart; M H Ellestad
Journal:  Am J Cardiol       Date:  1976-01       Impact factor: 2.778

10.  A controlled comparison of oxyfedrine, isosorbide dinitrate and placebo in the treatment of patients suffering attacks of angina pectoris.

Authors:  J Whittington; E B Raftery
Journal:  Br J Clin Pharmacol       Date:  1980-09       Impact factor: 4.335

  10 in total
  2 in total

1.  Comparison of oxyfedrine and atenolol in angina pectoris--a double-blind study.

Authors:  L Fananapazir; C Bray
Journal:  Br J Clin Pharmacol       Date:  1985-10       Impact factor: 4.335

2.  Effects of oxyfedrine on regional myocardial blood flow in patients with coronary artery disease.

Authors:  J C Kaski; L Araujo; A Maseri
Journal:  Cardiovasc Drugs Ther       Date:  1991-12       Impact factor: 3.727

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.